Equities research analysts expect that Novartis will post 8.42 EPS for the current fiscal year. Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in ...

The easiest way to invest in a diversified basket of European equities is via a mutual fund or exchange-traded fund that is indexed to that region's stock market. The U.S.-based ETF benchmarked to ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

PORTLAND, OR, UNITED STATES, February 15, 2025 /EINPresswire / -- Ankylosing spondylitis (AS) is a chronic inf ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.